Episode
Orca-T for GVHD–free survival and Understanding VEXAS anemia
- Podcast
- Blood Podcast
- Published
- Jun 25, 2026
- Duration seconds
- 1384
- Processing state
not_requested- Canonical source
- https://share.transistor.fm/s/ae7ba399
Actions
POST https://stenobird.com/v1/public/podcasts/blood-podcast-664776/episodes/orca-t-for-gvhd-free-survival-and-understanding-vexas-anemia/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/blood-podcast-664776/orca-t-for-gvhd-free-survival-and-understanding-vexas-anemia.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
In this week's episode, Blood editor Dr. Laurie Sehn interviews Drs. Everett Meyer and Olivier Hermine on their latest articles published in volume 147 issue 11 of Blood . Dr. Everett Meyer discusses " Orca-T vs allogeneic hematopoietic stem cell transplantation (PRECISION-T): a multicenter, randomized phase 3 trial " which demonstrated that Orca-T showed superior chronic GVHD–free survival compared to the control arm (78.0% vs 38.4%, P < .001) and lower nonrelapse mortality (3.4% vs 13.2%, P = .03). Dr. Olivier Hermine shares insights from " VEXAS anemia is a mosaic erythroblastopenia " which proposes that VEXAS syndrome–associated anemia should be considered as a mosaic erythroblastopenia, in which the severity of anemia is influenced by the quality and quantity of the UBA1 –wild-type compartment.